share_log

Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer

Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer

默克公司的Keytruda Combo試驗未能達到治療肝癌的主要目標
Benzinga Real-time News ·  2022/09/12 06:48
  • Merck & Co Inc (NYSE:MRK) and Eisai Co Ltd (OTC:ESALY) presented final analysis results from Phase 3 LEAP-002 of Keytruda plus Lenvima versus Lenvima as a first-line treatment for unresectable hepatocellular carcinoma (uHCC).
  • In the final analysis of the trial, there was a trend toward improvement for one of the study's dual primary endpoints, overall survival (OS); however, the results did not meet statistical significance.
  • Related: Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal.
  • The median OS was 21.2 months for Keytruda plus Lenvima and 19.0 months for Lenvima monotherapy.
  • Additionally, Keytruda plus Lenvima resulted in a trend toward improvement in progression-free survival (PFS) versus Lenvima monotherapy; however, the results did not meet the pre-specified threshold at the first interim analysis for statistical significance.
  • Price Action: MRK shares closed lower by 0.09% at $87.34 on Friday.
  • 默沙東(紐約證券交易所股票代碼：MRK)和衞材株式會社(場外交易代碼：ESALY)公佈了Keytruda Plus Lenvima與Lenvima作為不能切除的肝細胞癌(UHCC)一線治療方案的3期LEAP-002的最終分析結果。
  • 在試驗的最終分析中，研究的雙重主要終點之一--總體存活率(OS)有改善的趨勢；然而，結果並不符合統計學意義。
  • 相關： 默克公司的兩項Keytruda Combo癌症試驗未能達到預期的主要目標.
  • Keytruda加Lenvima的中位OS為21.2個月，Lenvima單一治療的中位OS為19.0個月。
  • 此外，Keytruda加Lenvima療法與Lenvima單一療法相比，在無進展存活率(PFS)方面有改善的趨勢；然而，在第一次中期分析中，結果沒有達到預先指定的閾值，具有統計學意義。
  • 價格行動：週五，Mr K股價收盤下跌0.09%，至87.34美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論